Immuron Limited
Immuron Limited (IMRN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · IMRN · as of Jun 9, 2026
Key Statistics
Explore Immuron Limited Data
imrn stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 1 · Buy rate: 100.0%
Competitors & Peers
imrn competitorsIMRN
APM
BOLT
BRTX
CLRB
COCPStock Performance
Full HistoryAbout Immuron Limited
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and …
what is immuron limited · imrn stock overview · immuron limited company profile · who is immuron limited ceo · imrn NASDAQ · immuron limited headquarters · immuron limited business segments
About Stock Overview & Key Data
Immuron Limited (IMRN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 9, 2017. As of the latest trading session, IMRN stock price is $1.20, with a market capitalization of $7.7M. The stock has returned -28.99% over the past 12 months and +57.38% year-to-date.
According to 1 Wall Street analysts, the consensus rating for Immuron Limited stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Immuron Limited reported revenue of $7.3M and net income of -$5.2M. For detailed data — including Immuron Limited revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Immuron Limited (IMRN) stock price is $1.20. The stock is traded on NASDAQ under the ticker symbol IMRN. The 52-week range is $0.68 – $2.39.